FDA Approves Qelbree, A Non-Stimulant ADHD Medication

On April 2, 2021, Supernus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Qelbree (viloxazine extended-release capsules), a non-stimulant medication for the treatment of attention-deficit hyperactivity disorder (ADHD) in children ages 6 to 17. Supernus plans to make Qelbree available in the United States in the second quarter of 2021. The medication comes as a capsule and the contents can be sprinkled over food.

Qelbree is a serotonin norepinephrine modulating agent, with viloxazine hydrochloride as the active ingredient. The medication can be sprinkled on food. It was tested in four Phase III . . .